Feature
MOTS-c: Where the Evidence Ends
Studies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?
Peter Attia Blog
Personalized medicine comes to cancer immunotherapy
A personalized mRNA vaccine (intismeran) plus PD‑1 inhibitors reduced recurrence or death in resected high‑risk melanoma.
Key takeaways
- The vaccine is customized from each patient's tumor DNA sequencing.
- Findings are from melanoma trials and are not broadly proven.
- Combination therapy showed lower recurrence and distant metastasis.
